ClinicalTrials.gg
Active, not recruitingNCT07295028VXB251-001Updated May 20, 2026

Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults

A Phase 1 interventional study of trivalent (RSV/hMPV/PIV3) vaccine candidate and trivalent (RSV/hMPV/PIV3) vaccine candidate in Lower Respiratory Tract Disease and Healthy Participants, sponsored by Sanofi. Active, not recruiting at 6 sites in Australia. Open to participants aged 60 Years to 83 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Sanofi · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
60 Years to 83 Years
Sex
All
01

Study summary

This study is being done to find out how safe and effective a new combined vaccine candidate, called VXB-251, is for older adults. The vaccine candidate is designed to protect against three common viruses that can cause respiratory tract infections:

  • RSV (respiratory syncytial virus)
  • hMPV (human metapneumovirus)
  • PIV3 (parainfluenza virus type 3)

Two components of this vaccine (RSV and hMPV) have already been tested in people before, as part of another study for a two-in-one vaccine. However, this is the first time that the PIV3 component and all three components together (RSV, hMPV, and PIV3) are being tested in people.

The vaccine candidate will be given as a single intramuscular injection. The study will also test unlicensed comparator vaccines and a placebo (a substance that looks like the real vaccine but doesn't contain any active ingredients) that target none, one or two of these viruses to see whether combining all three components affects safety or how well the immune system responds.

Read the detailed description

This is a multicenter randomized, placebo- and comparator-controlled, dose-ranging study to be conducted in Australia in older adults, aged 60 to 83 years, to evaluate the safety, reactogenicity, and immunogenicity of a trivalent RSV/hMPV/PIV3 vaccine candidate, VXB-251. All investigational medicinal products (IMPs) will be administered as a single 0.5 mL intramuscular injection on day 1.

Recruitment will be in 2 stages:

Stage 1 (N=10). Two cohorts, each of 5 participants, will be sequentially enrolled at a 4:1 ratio to receive:

  • Cohort 1: either a medium dose of the vaccine candidate or the placebo control,
  • Cohort 2: either a high dose of the vaccine candidate or the placebo control

At each enrolling site, at least 1 hour must elapse between IMP injection in the first sentinel and next IMP injection to monitor for hypersensitivity reactions and other fast-onset adverse events (AEs). The investigator or delegate will decide if and when the next sentinel can be vaccinated.

A Safety Monitoring Committee (SMC) will make recommendations on escalation from 1 sequential cohort to the next and progress from Stage 1 to Stage 2 based on 1-week safety and reactogenicity available data from the prior cohort.

Stage 2 (N=230). Participants will be concurrently assigned on day 1 (Visit 2) at an unequal ratio into 1 of 8 study groups and receive one of the following:

  • VXB-251 trivalent (RSV/hMPV/PIV3) vaccine candidate, low dose (N=30)
  • VXB-251 trivalent (RSV/hMPV/PIV3) vaccine candidate, medium dose (N=26)
  • VXB-251 trivalent (RSV/hMPV/PIV3) vaccine candidate, high dose (N=26)
  • VXB-241 bivalent (RSV/hMPV) unlicensed comparator (N=30)
  • VXB-213 monovalent (RSV) unlicensed comparator (N=30)
  • VXB-221 monovalent (hMPV) unlicensed comparator (N=30).
  • VXB-232 monovalent (PIV3) unlicensed comparator (N=30)
  • Placebo (N=28)

In Stage 1, the study will be open-label across cohorts and observer-blind within each cohort. In Stage 2, the study will be observer-blind.

The study duration for each participant will be 1 year.

02

Conditions studied

  • Lower Respiratory Tract Disease
  • Healthy Participants

Keywords

  • RSV
  • hMPV
  • PIV3
  • Multipathogen respiratory virus vaccines
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 83 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 60 to 83 years of age at inclusion.
  2. Evidence of signed and dated participant form (PICF) prior to any study procedure, indicating that the subject has been informed of all pertinent aspects of the study.
  3. Willingness and ability to comply with the planned study visits and calls, procedures, and restrictions for the duration of the study.
  4. Good health, which allows for pre-existing well controlled and low impact chronic diseases, except for the diseases listed in the exclusion criteria. A disease is defined as well controlled and has a low impact if it did not require meaningful change in therapy or unplanned medical visit(s) in the previous 3 months and allows participant's primary responsibility for self-care and daily living activities.
  5. Non-smoker or occasional smoker, defined as smoking less than 10 nicotine-containing cigarettes/ vapes/cigars/pipe fills per week.
  6. and childbearing/conception potential: only female participants with non- will be included. Male participants in a relationship with a female partner of childbearing potential must be willing to use a double contraceptive method together with their female partner for at least 4 weeks before and 12 weeks after the IMP injection at Visit 2 (day 1).
  7. (BMI) ≥ 17.0 kg/m2 and ≤ 35.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. History of RSV, hMPV, and/or PIV3 infection affecting the participant and/or the participant's household in the previous 12 months.
  2. History of disease (AID) or possibly autoimmune disease (pAID) requiring therapeutic intervention, even if stable and well controlled, including, but not limited to, systemic lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, temporal arteritis, psoriasis, insulin-dependent diabetes mellitus, celiac disease.
  3. Confirmed or suspected immunodeficiency, even if stable and well controlled.
  4. Ongoing severe asthma. Other allergic diseases (e.g., allergic rhinitis, atopic dermatitis / eczema, mild to moderate asthma, food allergies) are allowed at the investigator's or delegate's discretion.
  5. History of significant allergic reaction (e.g., anaphylaxis, , angioedema) to medication or food or known allergy to vaccine, or any in the formulation, and latex.
  6. History of severe AE associated with vaccine administration.
  7. Ongoing disorders of coagulation, which contraindicate IM injections.
  8. Donation or loss of ≥ 500 mL whole blood on the previous 2 months, and/or donation of plasma in the previous 1 week, and/or intention to donate blood or plasma during the study.
  9. Positive serum test results indicating ongoing , and/or infection, and/or documented ongoing HIV, HBV, or HCV infection.
  10. Other poorly controlled and/or impactful chronic disease. A disease is defined as poorly controlled if it requires meaningful change in therapy and/or unplanned medical visit(s) in the previous 3 months. A disease is defined as impactful if, in the investigator's judgment, it meaningfully affects the participant's ability to manage self-care and/or activities of daily living.
  11. Disease expected to prevent completion of the study (i.e. to rapidly deteriorate within the timeframe of the study).
  12. Prior treatments.

    1. Receipt of licensed RSV vaccine and/or enrollment in clinical trials(s) evaluating RSV, hMPV, PIV3, and/or molecular clamp-based vaccine candidates at any time, unless it was documented that the participant received a placebo.
    2. Other investigational drug or vaccine received in the previous 6 months.
    3. Chemotherapy, radiotherapy, and/or other medication (including biologics) received in the previous 6 months.
    4. IgGs or any blood product received in the previous 3 months.
    5. Systemic (oral/intravenous/IM) at doses equivalent to ≥ 20 mg prednisone per day received for ≥ 14 days, even if not consecutive, during the previous 3 months. Inhaled/nebulized, intra-articular, intra-bursal, skin, and eye topical corticosteroids are permitted.
    6. Received or plan to receive licensed non-(s) for the period starting 2 weeks before to 4 weeks after of the study IMP injection or licensed live vaccine(s) for the period starting from 4 weeks before to 4 weeks after the study IMP injection. Pandemic or emergency vaccines are always allowed as per country guidelines.
  13. abnormal finding from physical examination, vital sign assessment, (ECG), safety laboratory test results. If deemed appropriate, the investigator or delegate may repeat these assessments.
  14. History of alcohol abuse in the previous year determined at the investigator's discretion.
  15. History of recreational drug abuse in the previous year and/or positive test for drugs of abuse at Visit 2 (day 1), unless there is an explanation acceptable to the investigator (e.g., the participant has informed in advance that he/she consumed a prescription or over-the-counter product that contained the detected drug).
  16. Intention to participate in any investigational drug/vaccine/medical device clinical trial at any time throughout the planned duration of this study.
  17. Presence of tattoo, scarring, skin discoloration, or any other skin disturbances at the injection site which may interfere with effective assessment of the injection site.
  18. Intention to move to a location that would prevent participating in the study until study end.
  19. Any other reason which would prevent the participant from participating in the study or interfere with the participant's compliance with study procedures.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    VXB-251, low dose

    Biological: trivalent (RSV/hMPV/PIV3) vaccine candidate

  • Experimental
    VXB-251, medium dose

    Biological: trivalent (RSV/hMPV/PIV3) vaccine candidate

  • Experimental
    VXB-251, high dose

    Biological: trivalent (RSV/hMPV/PIV3) vaccine candidate

  • Experimental
    VXB-241

    Biological: bivalent (RSV/hMPV) unlicensed comparator

  • Experimental
    VXB-213

    Biological: monovalent (RSV) unlicensed comparator

  • Experimental
    VXB-221

    Biological: Biological/Vaccine: monovalent (hMPV) unlicensed comparator

  • Experimental
    VXB-232

    Biological: monovalent (PIV3) unlicensed comparator

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Biologicaltrivalent (RSV/hMPV/PIV3) vaccine candidate

    VXB-251 low dose, single, IM injection.

  • Biologicaltrivalent (RSV/hMPV/PIV3) vaccine candidate

    VXB-251 medium dose, single, IM injection.

  • Biologicaltrivalent (RSV/hMPV/PIV3) vaccine candidate

    VXB-251 high dose, single, IM injection.

  • Biologicalbivalent (RSV/hMPV) unlicensed comparator

    VXB-241 medium dose, single, IM injection.

  • Biologicalmonovalent (RSV) unlicensed comparator

    VXB-213 medium dose, single, IM injection.

  • BiologicalBiological/Vaccine: monovalent (hMPV) unlicensed comparator

    VXB-221 medium dose, single, IM injection.

  • Biologicalmonovalent (PIV3) unlicensed comparator

    VXB-232 medium dose, single, IM injection.

  • OtherPlacebo

    diluent, single, IM injection.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With 1 or More Unsolicited Adverse Events (AEs)

    Time frame: 1 month after IMP injection

  2. Proportion of Participants With 1 or More Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), and Premature Discontinuation Associated AEs (PDAEs)

    Time frame: 1 month after IMP injection

  3. Proportion of Participants With 1 or More Solicited AEs

    Time frame: 7 days after IMP injection

Secondary outcomes

  1. Proportion of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), and Premature Discontinuation Associated AEs (PDAEs)

    Time frame: 6 and 12 months after IMP injection

  2. Proportion of Participants With 1 or More Severe Solicited AEs

    Time frame: 7 days after IMP injection

  3. Geometric Mean Fold Increase (GMFI) of RSV-A, RSV-B, hMPV-A, hMPV-B, and PIV3 Serum Neutralizing Antibody Titers

    GMFI is defined as geometric mean of ratios of specific antibody titer/concentration at each post-injection time point over pre-injection baseline.

    Time frame: Pre-injection baseline to 1 month, 6 months, and 12 months, after IMP injection

  4. Geometric Mean Titers (GMTs) of RSV-A, RSV-B, hMPV-A, hMPV-B, and PIV3 Serum Neutralizing Antibody Titers

    Time frame: Pre-injection baseline to 1 month, 6 months, and 12 months after IMP injection

  5. Proportion of Participants with Sero-response Greater Than or Equal to (>=) 4-fold (SRR-4) and 8-fold (SRR-8) Increase from Baseline in Neutralizing Antibody Titers for RSV-A, RSV-B, hMPV-A, hMPV-B, and PIV3

    Time frame: Pre-injection baseline up to 1 month, 6 months, and 12 months after IMP injection

  6. GMFI of RSV PreF, hMPV PreF, and PIV3 PreF Serum Immunoglobulins G (IgG) Concentrations

    Time frame: Pre-injection baseline to 1 month, 6 months, and 12 months after IMP injection

  7. Geometric Mean Concentrations (GMC) of RSV PreF, hMPV PreF, and PIV3 PreF Serum IgG

    Time frame: 1 month, 6 months, and 12 months after IMP injection

  8. Geometric Mean Ratios (GMRs) of Fold Increase of RSV-A and RSV-B Neutralizing Serum Antibody Titers Versus Fold Increase of RSV PreF Serum IgG Concentration

    Time frame: Pre-injection baseline to 1 month, 6 months, and 12 months after IMP injection

  9. GMR of Fold Increase of hMPV-A and hMPV-B Neutralizing Serum Antibody Titers Versus Fold Increase of hMPV PreF Serum IgG Concentration

    Time frame: Pre-injection baseline to 1 month, 6 months, and 12 months after IMP injection

  10. GMR of Fold Increase of PIV3 Neutralizing Serum Antibody Titers Versus Fold Increase PIV3 PreF Serum IgG Concentration

    Time frame: Pre-injection baseline to 1 month, 6 months, and 12 months after IMP injection

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Apr 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 19, 2025
StartActual
Nov 17, 2025
Primary completionActual
Apr 21, 2026
CompletionEst.
Apr 24, 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07295028
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Nov 17, 2025
Primary completion
Apr 21, 2026
Completion
Apr 24, 2027 (estimated)
Last update
May 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion